This is illustrated in Supplementary Fig. 2a, b for Weibull fits to OS and PFS data for panitumumab in combination with FOLFIRI and for FOLFIRI alone in wild-type and mutant KRAS metastatic colorectal cancer (trial 2005018132; average R2 = 0.99 for OS curves and 0.92 for PFS curves). The gene discussed is KRAS; the disease is metastatic colorectal cancer.